Tonix Pharmaceuticals CEO Dr. Seth Lederman recently announced that their COVID vaccine, TNX-1800, has been selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID. The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines like TNX-1800 offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines.
This choice of TNX-1800 is a testament to Tonix’s nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics. This development highlights the significance of vaccine platforms for tackling various infectious threats.
Tonix’s approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform’s adaptability positions it as a valuable tool for future vaccine strategies. With this news coming from Steve Darling from Proactive in an exclusive interview with the journalist team at [Publication], we have high hopes for what this means not only for the fight against COVID but also for future pandemic preparedness efforts worldwide.